CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 446 target
Drug / intervention
MRG003 + Pucotenlimab +1 moredrug
Likely dose
Gemcitabine, Docetaxel, or Capecitabine 1000 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06976190
NCT06976190Phase 3RecruitingOn TrackUpdated 5mo ago
CompareCT.gov

A Randomized, Open-label, Multi-center, Phase III Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Shanghai Miracogen Inc.·interventional·Posted May 16, 2025·Updated Jan 20, 2026

In Brief

A Phase 3 clinical trial evaluating MRG003 + Pucotenlimab and Gemcitabine, Docetaxel, or Capecitabine for Recurrent or Metastatic Nasopharyngeal Carcinoma. Currently recruiting, targeting 446 participants across 1 site.

Detailed Summary

This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent or Metastatic Nasopharyngeal Carcinoma
CountriesChina
Collaborators--

Timeline

Phase 3Recruiting
202620272028202920302031
First PostedMay 16, 2025
Enrollment StartMay 6, 2025
Primary CompletionMay 1, 2029
Study CompletionDec 1, 2030
TodayJul 1, 2026
Enrollment to primary: 4.0 yearsPosted 1.1 years agoPrimary completion in 2.8 years

Interventions

MRG003 + Pucotenlimabdrug

MRG003 will be administrated as specified in the protocol. Pucotenlimab will be administrated as specified in the protocol.

Gemcitabine, Docetaxel, or Capecitabinedrug

Gemcitabine will be administrated via intravenous infusion at 1000 mg/m2 once on Day 1 and 8 of every 3 weeks (21-day cycle). Docetaxel will be administrated via intravenous infusion at 75 mg/m2 once on Day 1 of every 3 weeks (21-day cycle). Capecitabine will be administrated orally at 1000 mg/m2 twice a day for Day 1 to 14 of every 3 weeks (21-day cycle).